Laekna Past Earnings Performance
Past criteria checks 0/6
Laekna has been growing earnings at an average annual rate of 52.8%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 67.9% per year.
Key information
52.8%
Earnings growth rate
83.5%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 67.9% |
| Return on equity | -45.9% |
| Net Margin | -78,471.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Laekna makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -369 | 76 | 230 |
| 30 Sep 23 | 0 | -533 | 74 | 261 |
| 30 Jun 23 | 0 | -697 | 73 | 292 |
| 31 Mar 23 | 0 | -739 | 76 | 303 |
| 31 Dec 22 | 0 | -782 | 80 | 313 |
| 31 Dec 21 | 0 | -749 | 52 | 173 |
Quality Earnings: 2105 is currently unprofitable.
Growing Profit Margin: 2105 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2105's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2105's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2105 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 2105 has a negative Return on Equity (-45.87%), as it is currently unprofitable.